This document appears to be an assignment submitted by MD. Moshiur Rahman for their ACT 201 course section 47 at North South University. The assignment provides the balance sheet and cash flow statement for the company Beximco Pharma, including current assets of 8,366,279,107, long term assets of 20,634,246,854, current liabilities of 4,707,747,430, long term liabilities of 3,372,593,206, and owner's equity of 20,920,185,325. It also lists cash flows from operating activities of 2,217,408,357, investing activities of 2,276,146,837, and financing activities of 314,755
This document appears to be an assignment submitted by MD. Moshiur Rahman for their ACT 201 course section 47 at North South University. The assignment provides the balance sheet and cash flow statement for the company Beximco Pharma, including current assets of 8,366,279,107, long term assets of 20,634,246,854, current liabilities of 4,707,747,430, long term liabilities of 3,372,593,206, and owner's equity of 20,920,185,325. It also lists cash flows from operating activities of 2,217,408,357, investing activities of 2,276,146,837, and financing activities of 314,755
This document appears to be an assignment submitted by MD. Moshiur Rahman for their ACT 201 course section 47 at North South University. The assignment provides the balance sheet and cash flow statement for the company Beximco Pharma, including current assets of 8,366,279,107, long term assets of 20,634,246,854, current liabilities of 4,707,747,430, long term liabilities of 3,372,593,206, and owner's equity of 20,920,185,325. It also lists cash flows from operating activities of 2,217,408,357, investing activities of 2,276,146,837, and financing activities of 314,755